By monitoring the clinical symptoms and inflammation indicators in mice, it was found that during the same period of viral infection, when PPP was used to inhibit IGF1, the clinical symptoms of mice were alleviated; the lung injury area of the mice was reduced; the degree of lung injury was reduced; the lung index was significantly decreased; the serum levels of inflammatory cytokines IFN-γ, TNF-α, IL-1β, and IL-6 were significantly decreased; and the survival rate increased from 25 to 75% compared with the untreated group. This evidence concerns the gene IL1B and viral infectious disease.